NCT04648865View on ClinicalTrials.gov

A Study of LY3537031 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions
Healthy
Interventions
DRUG

LY3537031

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

162-0053

Clinical Research Hospital Tokyo, Shinjuku-ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04648865 - A Study of LY3537031 in Healthy Participants | Biotech Hunter | Biotech Hunter